The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs
Open accessAbstract
BACKGROUND: Concerns exist that women are underrepresented in trials of cardiovascular medications. OBJECTIVES: The authors sought to examine women's participation and the reported safety and efficacy by gender for pivotal cardiovascular disease (CVD) trials submitted to the U.S. Food and Drug Administration (FDA) supporting marketing applications. METHODS: On the basis of publicly available FDA reviews, the authors assessed enrollment of women in trials supporting 36 drug approvals from 2005 to 2015. Prevalence-corrected estimates for the participation of women were calculated as the percentage of women among trial participants divided by the percentage of women in the disease population (participation to prevalence ratio [PPR]), with a range between 0.8 and 1.2 reflecting similar representation of women in the trial and disease population. Sex differences in efficacy and safety were assessed. RESULTS: The proportion of women enrolled ranged from 22% to 81% (mean 46%). The calculated PPR by disease area was within or above the desirable range for atrial fibrillation (0.8 to 1.1), hypertension (0.9), and pulmonary arterial hypertension (1.4); PPR was <0.8 for heart failure (0.5 to 0.6), coronary artery disease (0.6), and acute coronary syndrome/myocardial infarction (0.6). The authors found little indication of clinically meaningful gender differences in efficacy or safety. Gender differences in efficacy or safety were described in labeling for 4 drugs. CONCLUSIONS: Women were well represented in trials of drugs for hypertension and atrial fibrillation, and overrepresented for pulmonary arterial hypertension. Representation of women fell below a PPR of 0.8 for trials in heart failure, coronary artery disease, and acute coronary syndrome. Minimal gender differences in drug efficacy and safety profiles were observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Lee, P. Y. (2001) · JAMA · doi:10.1001/jama.286.6.708 · Cited by 849
Representation of the Elderly, Women, and Minorities in Heart Failure Clinical Trials
Heiat, A., Gross, C. P., & Krumholz, H. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1682 · Cited by 723
Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart Failure
Rathore, S. S., Wang, Y., & Krumholz, H. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021266 · Cited by 690
Women and Ischemic Heart Disease
Shaw, L. J., Bugiardini, R., & Merz, C. N. B. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.098 · Cited by 662
Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention
Melloni, C., Berger, J. S., Wang, T. Y., Gunes, F., Stebbins, A., Pieper, K. S., Dolor, R. J., Douglas, P. S., Mark, D. B., & Newby, L. K. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.868307 · Cited by 455
Harris, D. J., & Douglas, P. S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430706 · Cited by 255
Sex Differences in Acute Coronary Syndrome Symptom Presentation in Young Patients
Khan, N. A. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.10149 · Cited by 227
Ding, E. L. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.9.905 · Cited by 197
Coakley, M., Fadiran, E. O., Parrish, L. J., Griffith, R. A., Weiss, E., & Carter, C. (2012) · Journal of Women's Health · doi:10.1089/jwh.2012.3733 · Cited by 186
Cited by
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
Laufs, U., Banach, M., Mancini, G. B. J., Gaudet, D., Bloedon, L. T., Sterling, L. R., Kelly, S., & Stroes, E. S. G. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011662 · Cited by 432
Women’s Participation in Cardiovascular Clinical Trials From 2010 to 2017
Jin, X., Chandramouli, C., Allocco, B., Gong, E., Lam, C. S. P., & Yan, L. L. (2020) · Circulation · doi:10.1161/circulationaha.119.043594 · Cited by 403
Cardiovascular Disease and the Female Disadvantage
Woodward, M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16071165 · Cited by 329
A 10-year follow-up study of sex inclusion in the biological sciences
Woitowich, N. C., Beery, A., & Woodruff, T. (2020) · eLife · doi:10.7554/elife.56344 · Cited by 320
Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome
Haider, A., Bengs, S., Luu, J., Osto, E., Siller-Matula, J. M., Muka, T., & Gebhard, C. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz898 · Cited by 305
Metadata
- Authors
- Scott, P. E., Unger, E. F., Jenkins, M. R., Southworth, M. R., McDowell, T.-Y., Geller, R. J., Elahi, M., Temple, R. J., & Woodcock, J.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 71
- Issue
- 18
- Pages
- 1960-1969
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2800815486
- Cited by
- 366
- References
- 31
- FWCI
- 29.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs. https://app.cochat.ai/papers/10.1016/j.jacc.2018.02.070
- The paper
- Scott, P. E., Unger, E. F., Jenkins, M. R., Southworth, M. R., McDowell, T.-Y., Geller, R. J., Elahi, M., Temple, R. J., & Woodcock, J. (2018). Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2018.02.070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.